Global ARCC Trial. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
New England Journal of Medicine (Impact Factor: 55.87). 05/2007; 356(22):2271-81. DOI: 10.1056/NEJMoa066838
Source: PubMed


Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.
In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) subcutaneously three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly. The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group.
Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P=0.008) and progression-free survival (P<0.001) than did patients who received interferon alone. Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P=0.70). Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 months, respectively. Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group. There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02).
As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. ( number, NCT00065468 [].).

Download full-text


Available from: Anil Kapoor, Feb 18, 2014
56 Reads
  • Source
    • "). Over the past decade, the US Food and Drug Administration has approved several drugs targeting vascular endothelial growth factor and mammalian target of rapamycin pathways, including sorafenib (Escudier et al, 2007a), sunitinib (Motzer et al, 2007), bevacizumab (Escudier et al, 2007b), temsirolimus (Hudes et al, 2007), everolimus (Motzer et al, 2010), pazopanib (Sternberg et al, 2013), and axitinib (Motzer et al, 2013). These drugs have shown better clinical outcomes than the traditional therapies, but most cancers exhibit drug resistance within a year on drug and the drugs have significant side effects (Harada et al, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Axl plays multiple roles in tumourigenesis in several cancers. Here we evaluated the expression and biological function of Axl in renal cell carcinoma (RCC). Axl expression was analysed in a tissue microarray of 174 RCC samples by immunostaining and a panel of 11 normal tumour pairs of human RCC tissues by western blot, as well as in RCC cell lines by both western blot and quantitative PCR. The effects of Axl knockdown in RCC cells on cell growth and signalling were investigated. The efficacy of a humanised Axl targeting monoclonal antibody hMAb173 was tested in histoculture and tumour xenograft. We have determined by immunohistochemistry (IHC) that Axl is expressed in 59% of RCC array samples with moderate to high in 20% but not expressed in normal kidney tissue. Western blot analysis of 11 pairs of tumour and adjacent normal tissue show high Axl expression in 73% of the tumours but not normal tissue. Axl is also expressed in RCC cell lines in which Axl knockdown reduces cell viability and PI3K/Akt signalling. The Axl antibody hMAb173 significantly induced RCC cell apoptosis in histoculture and inhibited the growth of RCC tumour in vivo by 78%. The hMAb173-treated tumours also had significantly reduced Axl protein levels, inhibited PI3K signalling, decreased proliferation, and induced apoptosis. Axl is highly expressed in RCC and critical for RCC cell survival. Targeting Axl is a potential approach for RCC treatment.British Journal of Cancer advance online publication, 16 July 2015; doi:10.1038/bjc.2015.237
    British Journal of Cancer 07/2015; 113(4). DOI:10.1038/bjc.2015.237 · 4.84 Impact Factor
  • Source
    • "Sunitinib [3], sorafenib [4], axitinib [5], pazopanib [6] and bevacizumab + interferon [7] have all been registered for the treatment of advanced RCC. Additionally, the mTOR inhibitors Temsirolimus and Everolimus have been registered for poor risk RCC patients [8] [9]. Implementation of these new treatment modalities has lead to an impressive increase in progression-free survival [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable. We combined sunitinib, targeting the endothelial cells with Girentuximab (monoclonal antibody cG250, recognizing carbonic anhydrase IX (CAIX) targeting the tumor cells to study the effect of sunitinib on the biodistribution of Girentuximab because combination of modalities targeting tumor vasculature and tumor cells might result in improved effect. Nude mice with human RCC xenografts (NU12, SK-RC-52) were treated orally with 0.8 mg/day sunitinib, or vehicle for 7 to 14 days. Three days before start or cessation of treatment mice were injected i.v. with 0.4 MBq/5 μg (111)In-Girentuximab followed by biodistribution studies. Immunohistochemical analyses were performed to study the tumor vasculature and CAIX expression and to confirm Girentuximab uptake. NU12 appeared to represent a sunitinib sensitive tumor: sunitinib treatment resulted in extensive necrosis and decreased microvessel density (MVD). Accumulation of Girentuximab was significantly decreased when sunitinib treatment preceded the antibody injection but remained unchanged when sunitinib followed Girentuximab injection. Cessation of therapy led to a rapid neovascularization, reminiscent of a tumor flare. SK-RC-52 appeared to represent a sunitinib-resistant tumor: (central) tumor necrosis was minimal and MVD was not affected. Sunitinib treatment resulted in increased Girentuximab uptake, regardless of the sequence of treatment. These data indicate that sunitinib can be combined with Girentuximab. Since these two modalities have different modes of action, this combination might lead to enhanced therapeutic efficacy. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Neoplasia (New York, N.Y.) 02/2015; 49(2). DOI:10.1016/j.neo.2014.12.011 · 4.25 Impact Factor
  • Source
    • "On the other hand, in more than three hundred and seventy poor-risk patients treated with sunitinib in the expanded access trial, a median PFS and OS of 4.1 and 10.9 months respectively was reached [22]. Even if this outcome is comparable to the positive result of the Global ARCC Trial which tested the mTOR inhibitor temsirolimus over IFN in the same group of patients [6], it did not reach the necessary level of evidence to be recommended as a first option by the European and US guidelines [23] [24], despite results of a recent large phase II trial that confirmed the superiority of VEGF/VEGFR inhibition over everolimus in first-line treatment, reporting a median PFS of 10.7 months for sunitinib compared with 7.9 months for everolimus , and a huge difference in terms of OS: 32.0 and 22.4 months, respectively [25]. No definitive conclusion can be drawn because the majority of patients were low-and intermediate-risk , and everolimus has been reported to differ from temsirolimus, at least when used as second-line therapy [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the improvement in progression-free survival and response rates, none of the five anti-VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported significant increase in patients' survival. This analysis aims to investigate their effect on overall survival (OS) performing a meta-analysis of the available studies. MEDLINE/PubMed and Cochrane Library were searched for randomized phase III trials that compared anti-VEGF/VEGFR agents with controls as upfront treatment for mRCC. The search was restricted to phase III trials and data extraction was conducted according to the PRISMA statement. Five randomized phase III trials were included for a total of 3,469 patients; among these 1,801 received anti-VEGF/VEGFR agents and 1,668 were treated with a placebo or interferon-α. In the overall population the reduction of the risk of death was 13% (HR: 0.87; 95%CI, 0.80 - 0.95; p=0.002). When patients were divided based on use of VEGFR agents or anti-VEGF monoclonal antibody, the reduction of the risk of death was 13% and 12%, respectively. If only treatment naïve patients were considered, we confirm a significant reduction of 12% (HR=0.88; 95%CI, 0.79 - 0.97; p=0.010), in the risk of death. Our analysis reports a positive improvement of OS with the inhibition of VEGF/VEGFR pathway in mRCC.
    Current Drug Targets 11/2014; 16(2). DOI:10.2174/1389450115666141120120145 · 3.02 Impact Factor
Show more